Pharmaceuticals News and Research

RSS

Lupin’s Fenofibrate tablets now available in the U.S.

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has launched its Fenofibrate Tablets, 48 mg and 145 mg strengths in the United States. Lupin had earlier received final approval for the same from the US Food and Drug Administration (FDA).

21 Nov 2012

UBC microbiologist receives Prix Galien 2012 Research Award

UBC microbiologist Robert E.W. Hancock has received the Prix Galien 2012 Research Award, widely considered the most prestigious honour in Canadian pharmaceutical research and innovation. Hancock is being recognized for pioneering work unravelling the complex interactions between antibiotics and bacteria.

20 Nov 2012

Commitment, teamwork needed to control, eliminate NTDs by 2020

The focus of the Uniting to Combat Neglected Tropical Diseases: Translating the London Declaration into Action conference, which took place November 16-18 in Washington, D.C., was "how we can work together to put the right systems in place and implement the change needed" to control or eliminate neglected tropical diseases (NTDs) by 2020, Simon Bush, director of NTDs at Sightsavers, writes in the Huffington Post U.K.'s "Impact" blog.

20 Nov 2012

Drug shortages a new way of life in providing care; Lawmakers call for investigation

As health care facilities struggle to keep inventories of key medicines, some are resorting to risky practices. Meanwhile, six members of Congress seek GAO probe of pharmaceutical contracting so see if it has hurt generic drugmakers and added to shortages.

20 Nov 2012

CFFT announces major expansion of research collaboration with Pfizer

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.

20 Nov 2012

Patheon to launch $30 million transferable rights offering

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it will launch a U.S. $30 million transferable rights offering.

19 Nov 2012

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).

19 Nov 2012

KemPharm announces successful Type B meeting with FDA for KP201

KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today a successful Type B meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201.

19 Nov 2012

HORIBA Europe opens new R&D facility

HORIBA Europe has inaugurated its new research and technology center at the Saclay Technopole. Atsushi Horiba, President of the HORIBA Group, cut the ribbon opening the doors to HORIBA’s home for scientific innovation and cooperation.

19 Nov 2012

FDA accepts Orexo’s Zubsolv NDA for review

FDA has informed Orexo that the Zubsolv New Drug Application (NDA) has been accepted for review, and that the Prescription Drug User Fee Act (PDUFA) action date will be July 6, 2013.

19 Nov 2012

Massimo CEO wins Ernst & Young Entrepreneur Of The Year Award

Joe Kiani, founder, CEO and Chairman of the Board of Massimo Corporation, has been named the Ernst & Young National Entrepreneur Of The Year 2012 Life Sciences Award Winner.

19 Nov 2012

United States Pharmacopeial Convention to host Fifth Bioassay Workshop in Rockville

As a growing number of biologic drugs are treatments of choice for an expanding list of autoimmune disorders, inflammatory diseases, and certain cancers, bioassays play a critical role in establishing the functional integrity and potency of these products.

17 Nov 2012

Study illuminates how Aldo and galectin-3 protein contribute to vascular remodeling, CHF

Cardiovascular disease will kill nearly 2.5 million people in the United States this year, according to the Centers for Disease Control. Over time, inflammation, collagen deposition and scar tissue formation can cause blood vessels to stiffen, a process called vascular fibrosis. Though researchers have known that the hormone aldosterone (Aldo) plays a role in this process, the precise mechanisms have been poorly understood.

17 Nov 2012

FDA approves Cook's Zilver PTX drug-eluting peripheral stent

Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.

16 Nov 2012

Experts call for global treaty on drug quality

Professionals from the world of health, including health charities, legal and medical academia, and former or current government health officials, have called for the creation of an internationally binding treaty to tackle illegitimate drugs.

16 Nov 2012

GigaScience announces publication of whole-genome sequencing and analysis of Wuzhishan Pig

The international open-access journal GigaScience announces the publication of the whole-genome sequencing and analysis of the Wuzhishan Pig, an extensively inbred, miniature pig, which can serve as an excellent model for human medical research.

16 Nov 2012

Thermo Fisher announces opening of new facility in Suzhou, China

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its new facility in Suzhou, China, for the manufacturing of life sciences consumables and equipment. The facility expands the company's global manufacturing footprint and establishes local production capabilities to meet increased customer demand in China and other Asia-Pacific markets.

From Thermo Fisher Scientific Inc. 16 Nov 2012

Positive results from POZEN’s PA8140-102 Phase 1 bioavailability study

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that the results from a Phase 1 study, PA8140-102, demonstrated that PA8140, POZEN's proprietary combination of aspirin (81 mg) and omeprazole (40 mg), had comparable bioavailability relative to the reference listed product, enteric-coated (EC) aspirin (81 mg).

16 Nov 2012

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.

15 Nov 2012

Objections from India bar experts calling for global treaty against fake drug trade from WHO meeting

"A group of experts calling for a global treaty to stop the lethal trade in fake medicines has been barred from attending a World Health Organization meeting, highlighting deep divisions that are blocking progress on the subject," Reuters reports (Hirschler, 11/13).

15 Nov 2012